See more : Allot Ltd. (ALLT.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Acer Therapeutics Inc. (ACER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acer Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kolibri Global Energy Inc. (KGEI) Income Statement Analysis – Financial Results
- 36Kr Holdings Inc. (KRKR) Income Statement Analysis – Financial Results
- Ceridian HCM Holding Inc. (CDAY.TO) Income Statement Analysis – Financial Results
- Tega Industries Limited (TEGA.NS) Income Statement Analysis – Financial Results
- Artemis Resources Limited (ARV.AX) Income Statement Analysis – Financial Results
Acer Therapeutics Inc. (ACER)
About Acer Therapeutics Inc.
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 1.26M | 0.00 | 0.00 | 432.12K | -246.30K | 2.91M | 2.56M | 1.27M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.45K | 46.45K | 0.00 | 0.00 | 3.92K | 16.05K | 249.57K | 816.24K | 2.90M |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 266.04K | 687.51K | 2.54M |
Gross Profit | 0.00 | 1.26M | 0.00 | 0.00 | 432.12K | -246.30K | 2.91M | 2.56M | 1.27M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.45K | 46.45K | 0.00 | 0.00 | 3.92K | 16.05K | -16.47K | 128.73K | 363.10K |
Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | -6.60% | 15.77% | 12.51% |
Research & Development | 11.92M | 6.51M | 11.85M | 13.85M | 12.45M | 8.73M | 6.50M | 10.04M | 12.12M | 9.18M | 6.32M | 3.34M | 2.58M | 2.11M | 8.39M | 13.07M | 7.61M | 9.89M | 632.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 12.69M | 10.70M | 10.95M | 16.05M | 9.26M | 5.22M | 3.12M | 4.26M | 3.83M | 3.67M | 2.51M | 0.00 | 2.22M | 2.02M | 0.00 | 0.00 | 5.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 12.69M | 10.70M | 10.95M | 16.05M | 9.26M | 5.22M | 3.12M | 4.26M | 3.83M | 3.67M | 2.51M | 2.41M | 2.22M | 2.02M | 3.34M | 3.42M | 5.46M | 550.18K | 3.13M | 120.35K | 130.29K | 528.35K | 975.65K | 685.81K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.63K | 68.70K | 2.15K | 37.91K | 303.68K | 219.94K | 169.30K | 216.62K | 237.16K | 246.15K | 1.82M | 1.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 24.61M | 17.21M | 22.80M | 29.90M | 21.71M | 13.95M | 9.86M | 14.65M | 16.34M | 13.19M | 9.13M | 5.97M | 4.97M | 4.35M | 11.97M | 16.74M | 14.90M | 12.20M | 3.76M | 121.84K | 160.30K | 528.35K | 975.65K | 730.47K |
Cost & Expenses | 24.61M | 17.21M | 22.80M | 29.90M | 21.71M | 13.95M | 9.86M | 14.65M | 16.34M | 13.19M | 9.13M | 5.97M | 4.97M | 4.35M | 11.97M | 16.74M | 14.90M | 12.20M | 3.76M | 121.84K | 160.30K | 794.38K | 1.66M | 3.27M |
Interest Income | 1.82K | 49.27 | 13.58K | 471.27K | 412.55K | 14.85K | 0.00 | 0.00 | 15.46K | 14.99K | 280.00 | 932.00 | 1.66K | 1.76K | 100.24K | 477.61K | 688.30K | 81.93K | 5.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 101.43K | 0.00 | 0.00 | 0.00 | 987.00 | 245.06K | 0.00 | 0.00 | 1.98K | 2.27M | 350.30K | 3.14K | 500.65K | 278.13K | 19.98K | 16.10K | 984.00 | 7.32M | 868.93K | 55.06K | 54.16K | 55.40K | 33.71K | 13.95K |
Depreciation & Amortization | -198.47K | -54.76K | 96.20K | -8.21K | 27.74K | 4.00K | 238.13K | 351.40K | 387.78K | 335.60K | 303.68K | 210.25K | 168.84K | 214.85K | 234.33K | 232.96K | 1.82M | 7.25M | 1.02M | 1.48K | 12.95K | 15.40K | 19.41K | 19.13K |
EBITDA | -24.55M | -15.88M | -22.73M | -28.34M | -21.25M | -13.95M | -6.70M | -2.57M | -14.66M | -11.53M | -8.83M | -5.76M | -4.80M | -7.32M | -11.77M | -18.10M | -13.23M | -4.95M | -2.74M | -201.83K | -113.49K | -531.89K | -827.39K | -551.31K |
EBITDA Ratio | 0.00% | -1,270.09% | 0.00% | 0.00% | -4,929.34% | 5,656.94% | -195.37% | -459.26% | -1,152.81% | -910.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -38,961.47% | -28,472.35% | 0.00% | 0.00% | -5,155.33% | -707.07% | -213.13% | -101.37% | -19.00% |
Operating Income | -24.61M | -15.95M | -22.80M | -29.90M | -21.71M | -13.95M | -7.99M | -12.09M | -15.07M | -11.92M | -9.13M | -5.97M | -4.97M | -4.35M | -11.97M | -16.74M | -14.90M | -12.20M | -3.76M | -117.92K | -144.25K | -544.82K | -846.92K | -367.37K |
Operating Income Ratio | 0.00% | -1,265.75% | 0.00% | 0.00% | -5,024.81% | 5,662.97% | -275.08% | -473.10% | -1,184.68% | -941.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -36,030.81% | -32,067.06% | 0.00% | 0.00% | -3,012.06% | -898.67% | -218.31% | -103.76% | -12.66% |
Total Other Income/Expenses | -1.62M | 574.40K | -82.62K | -1.02M | 433.10K | -246.30K | -1.28M | 74.61K | 15.62K | -4.73M | 202.96K | -3.14K | -498.99K | 2.91M | 115.15K | 2.68M | 838.74K | -7.21M | -860.56K | 85.39K | -17.80K | 2.47K | -120.00 | 203.07K |
Income Before Tax | -26.24M | -15.37M | -22.89M | -29.42M | -21.28M | -14.19M | -7.98M | -12.02M | -15.05M | -16.66M | -8.93M | -5.97M | -5.47M | -1.43M | -11.85M | -14.67M | -14.06M | -19.41M | -4.62M | -32.53K | -162.05K | -542.34K | -847.04K | -164.30K |
Income Before Tax Ratio | 0.00% | -1,220.16% | 0.00% | 0.00% | -4,924.81% | 5,762.97% | -274.69% | -470.18% | -1,183.45% | -1,315.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,576.68% | -30,261.37% | 0.00% | 0.00% | -830.91% | -1,009.56% | -217.32% | -103.77% | -5.66% |
Income Tax Expense | 1.62M | -645.31K | 11.81K | -537.75K | -432.12K | 246.30K | 1.04M | -4.74K | 4.13K | 2.31M | -202.96K | 5.97M | 5.47M | 1.43M | 11.85M | 14.67M | 14.06M | 19.41M | 4.62M | -30.33K | 54.91K | 52.93K | 33.83K | -189.12K |
Net Income | -27.86M | -14.73M | -22.90M | -28.88M | -21.28M | -14.19M | -7.98M | -12.02M | -15.05M | -16.66M | -8.93M | -5.97M | -5.47M | -1.43M | -11.85M | -14.67M | -14.06M | -19.41M | -4.62M | -87.59K | -199.16K | -597.74K | -880.75K | -178.25K |
Net Income Ratio | 0.00% | -1,168.94% | 0.00% | 0.00% | -4,924.81% | 5,762.97% | -274.69% | -470.18% | -1,183.45% | -1,315.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,576.68% | -30,261.37% | 0.00% | 0.00% | -2,237.24% | -1,240.76% | -239.51% | -107.90% | -6.14% |
EPS | -1.77 | -1.03 | -2.06 | -2.86 | -2.49 | -3.84 | -11.72 | -21.26 | -39.65 | -91.56 | -113.13 | -77.65 | -93.91 | -33.48 | -329.28 | -642.07 | -764.35 | -363.69 | -2.15K | -385.85 | -4.86K | -13.90K | -18.35K | -3.79K |
EPS Diluted | -1.77 | -1.03 | -2.06 | -2.86 | -2.49 | -3.84 | -11.72 | -21.26 | -39.65 | -91.56 | -113.13 | -77.65 | -93.91 | -33.48 | -329.28 | -642.07 | -764.35 | -363.69 | -2.15K | -385.85 | -4.86K | -13.90K | -18.35K | -3.79K |
Weighted Avg Shares Out | 15.77M | 14.27M | 11.12M | 10.09M | 8.56M | 3.69M | 680.67K | 565.35K | 379.63K | 181.92K | 78.94K | 76.87K | 58.24K | 42.83K | 35.99K | 22.84K | 18.39K | 53.38K | 2.15K | 227.00 | 41.00 | 43.00 | 48.00 | 47.00 |
Weighted Avg Shares Out (Dil) | 15.77M | 14.27M | 11.12M | 10.09M | 8.56M | 3.69M | 680.67K | 565.35K | 379.63K | 181.92K | 78.94K | 76.87K | 58.24K | 42.83K | 35.99K | 22.84K | 18.39K | 53.38K | 2.15K | 227.00 | 41.00 | 43.00 | 48.00 | 47.00 |
Acer's Spin 7 laptop uses Qualcomm's new Snapdragon chip for 5G connectivity
Acer Swift 3 and Swift 5 get updated with 11th Gen Intel, more - 9to5Toys
NVIDIA launches RTX 3070, 3080, and 3090 priced from $499 - 9to5Toys
The Acer Swift 3 and Swift 5 put Intel's Tiger Lake CPU into affordable laptops
Acer TravelMate P6 review
10 Best Cheap Gaming Laptops Under $1000 In 2020
Acer Chromebook 714 review
These are the best Chromebooks to buy for you and your family
'A gardening career was not what was expected of me': one man's journey from law to lawn
Acer’s Swift 3 is a solid laptop for students
Source: https://incomestatements.info
Category: Stock Reports